Evidence map›Paper›PMID 27241647›Full record

ArticleThe Indian journal of medical research2016

Demographic profile, host, disease & viral predictive factors of response in patients with chronic hepatitis C virus infection at a tertiary care hospital in north India.

Sreejith Vasudevan, Shalimar, Amit Kavimandan, Nancy Kalra, Baibaswata Nayak, Bhaskar Thakur, Prasenjit Das, Siddhartha Datta Gupta, Subrat Kumar Panda, Subrat Kumar Acharya

Open access · diamondAbstract read
In one paragraph

Article in The Indian journal of medical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Virusdisease · 2019
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Sreejith VasudevanDepartment of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
Shalimar
Amit KavimandanDepartment of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
Nancy KalraDepartment of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
Baibaswata NayakDepartment of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
Bhaskar ThakurDepartment of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.
Prasenjit DasDepartment of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Siddhartha Datta GuptaDepartment of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Subrat Kumar PandaDepartment of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Subrat Kumar AcharyaDepartment of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
All India Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

objectivesStandard of care for chronic hepatitis C (CHC) in India is peginterferon and ribavirin (RBV). The response to treatment in real life stetting is unclear. The objectives of this study were to evaluate the demographic profile and assess the virological response and predictors of response in CHC patients.

methodsConsecutive patients with CHC were included in this study. Detailed clinical history, risk factors, and predictive factors of response were noted. Patients were treated with peginterferon α2b (1.5 µg/kg/wk) and RBV (12 mg/kg/day) for 6 to 18 months based on response.

resultsA total of 211 patients were included in the analysis, mean age 40.6±12.3 yr, 144 (68%) were males and 71 (34%) had compensated cirrhosis. Commonest risk factor for acquiring CHC was previous transfusion and surgery (51%). Genotype 3 (72%) was most common followed by genotype 1 (23%). Overall sustained virologic response (SVR) was 64 per cent [95% CI 57.1%-70.4%]. The SVR was 66.5 per cent [95% CI 58.34-73.89%] for genotype 3 and 61.2 per cent [95% CI 46.23 to 74.80%] for genotype 1. Non-cirrhotics had better SVR rates compared to cirrhotics (76 vs 41%, p<0.001). On multivariate analysis, BMI ≥23 kg/m2, HOMA-IR ≥2, compliance (≤80%), and fibrosis >2 were predictors of low SVR. INTERPRETATION &

conclusionsGenotype 3 was the commonest HCV genotype. The commonest source of infection was previous transfusion and surgery. SVR rates for genotypes 3 were better than genotype 1 patients. Predictors of non-response were high BMI, insulin resistance, significant fibrosis and inadequate compliance.

Indexed as

AdultAgedFemaleHepacivirusHepatitis C, ChronicHumansIndiaInterferon-alphaInterferon alpha-2Liver CirrhosisMaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsRibavirinSustained Virologic ResponseInterferon-alphaInterferon alpha-2peginterferon alfa-2bPolyethylene GlycolsRecombinant ProteinsRibavirin

Identifiers

PMID27241647
PMCPMC4892080
OpenAlexW2401120685

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.